Cefotaxime sodium

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

头孢噻肟是第三代头孢菌素类抗生素。与其他第三代头孢菌素一样，它对革兰氏阳性菌和革兰氏阴性菌具有广谱活性。

Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis). (In Vitro):Cefotaxime sodium exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6.(In Vivo):The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens.

Cefotaxime sodium exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6.

The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens. Animal Model:Female, specific pathogen free, 8-week-old BALB/c mice.Dosage:30 mg/kg.Administration:IP every 6 h.Result:The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each).

——

GPCR/G Protein

Antibacterial

PBPs

Infection

——

64485-93-4

477.44

C16H16N5NaO7S2

>98% (HPLC)

DMSO: 47mg/mL

CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)[O-].[Na+]

——

(-20℃)

With Ice Pack

≥ 2 years